Avicanna (TSE:AVCN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Avicanna has successfully completed its first delivery of proprietary topical products to a multinational pharmaceutical company, marking a significant step in its European commercial expansion. The products, which include CBD and CBG-based formulations, are set to launch in six European countries in 2025, leveraging the pharmaceutical company’s established infrastructure.
For further insights into TSE:AVCN stock, check out TipRanks’ Stock Analysis page.